RxDoctor Payments Data

Alejandro Bevacqua, MD

Ophthalmology · Bergenfield, NJNPI 1487670865

Payments from drug & device makers

$2,457in general payments, 2019–2025

Across 132 payments — averaging $18.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$458
  • AbbVie$337
  • Bausch & Lomb Americas Inc.$313
  • Tarsus Pharmaceuticals, Inc.$184
  • NEW World Medical,inc.$155
  • Dompe US, Inc.$143
  • plus $866 from 13 others

What the payments were for

  • Food & beverage$2,457100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,457 in reported general payments places this provider in the 65th percentile of 583 ophthalmology providers in New Jersey.

See all ophthalmology providers in New Jersey

Medicare billing

Part B allowed, 2024
$265,473
Medicare patients
667
Services billed
1,936

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MieboPerfluorohexyloctane/Pf21$22,791
XiidraLifitegrast24$18,785
RestasisCyclosporine19$16,257
LumiganBimatoprost19$9,259
Cyclosporine15$8,858
EysuvisLoteprednol Etabonate12$5,957
Tobramycin-DexamethasoneTobramycin/Dexamethasone103$4,108
Timolol Maleate59$2,203
Prednisolone Acetate73$2,022
Latanoprost116$1,577
Ketorolac Tromethamine32$549
Ofloxacin35$349
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat11$294
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha24$221

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Miebo, Xiidra$313$41,57645 claims
AbbVieRestasis, Lumigan$337$25,51638 claims
Kala Pharmaceuticals, Inc.Eysuvis$66$5,95712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 583 ophthalmology providers in New Jersey.

Other ophthalmology in Bergenfield

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →